Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Medulloblastoma: Distinctive Histo-Molecular Correlation with Clinical Profile, Radiologic Characteristics, and Surgical Outcome.

Narayan V, Sugur H, Jaiswal J, Arvinda HR, Arivazhagan A, Somanna S, Santosh V.

Pediatr Neurosurg. 2019;54(5):329-340. doi: 10.1159/000501913. Epub 2019 Sep 3.

PMID:
31480064
2.

Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.

Zhang ZY, Xu J, Ren Y, Li KK, Ng HK, Mao Y, Zhong P, Yao Y, Zhou LF.

PLoS One. 2014 Jun 16;9(6):e99490. doi: 10.1371/journal.pone.0099490. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105742. PLoS One. 2014;9(9):e107855.

3.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.

Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1.

4.
5.

Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery.

Schneider C, Ramaswamy V, Kulkarni AV, Rutka JT, Remke M, Tabori U, Hawkins C, Bouffet E, Taylor MD.

J Neurosurg Pediatr. 2015 Mar;15(3):236-42. doi: 10.3171/2014.9.PEDS14280. Epub 2014 Dec 19.

PMID:
25525930
6.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD.

Lancet Oncol. 2016 Apr;17(4):484-495. doi: 10.1016/S1470-2045(15)00581-1. Epub 2016 Mar 12.

7.

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.

von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S.

J Clin Oncol. 2016 Dec;34(34):4151-4160. Epub 2016 Oct 31.

PMID:
27863192
8.

A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience.

Jiang T, Zhang Y, Wang J, Du J, Raynald, Qiu X, Wang Y, Li C.

Front Neurol. 2017 May 12;8:198. doi: 10.3389/fneur.2017.00198. eCollection 2017.

9.

Molecular subgroups of adult medulloblastoma: a long-term single-institution study.

Zhao F, Ohgaki H, Xu L, Giangaspero F, Li C, Li P, Yang Z, Wang B, Wang X, Wang Z, Ai L, Zhang J, Luo L, Liu P.

Neuro Oncol. 2016 Jul;18(7):982-90. doi: 10.1093/neuonc/now050. Epub 2016 Apr 21.

10.

Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute.

Huang PI, Lin SC, Lee YY, Ho DM, Guo WY, Chang KP, Chang FC, Liang ML, Chen HH, Liu YM, Yen SH, Wong TT, Chen YW.

Childs Nerv Syst. 2017 Aug;33(8):1285-1294. doi: 10.1007/s00381-017-3435-9. Epub 2017 May 9.

PMID:
28488086
11.

Medulloblastoma in childhood-King Edward Memorial hospital surgical experience and review: Comparative analysis of the case series of 365 patients.

Muzumdar D, Deshpande A, Kumar R, Sharma A, Goel N, Dange N, Shah A, Goel A.

J Pediatr Neurosci. 2011 Oct;6(Suppl 1):S78-85. doi: 10.4103/1817-1745.85717.

12.

Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases.

Yu J, Zhao R, Shi W, Li H.

Clinics (Sao Paulo). 2017 May;72(5):294-304. doi: 10.6061/clinics/2017(05)07. Retraction in: Clinics (Sao Paulo). 2017 Dec;72 (12 ):790.

13.

Survival and prognostic factors in a series of adults with medulloblastomas.

Riffaud L, Saikali S, Leray E, Hamlat A, Haegelen C, Vauleon E, Lesimple T.

J Neurosurg. 2009 Sep;111(3):478-87. doi: 10.3171/2009.1.JNS081004.

PMID:
19231932
14.

Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

von Bueren AO, von Hoff K, Pietsch T, Gerber NU, Warmuth-Metz M, Deinlein F, Zwiener I, Faldum A, Fleischhack G, Benesch M, Krauss J, Kuehl J, Kortmann RD, Rutkowski S.

Neuro Oncol. 2011 Jun;13(6):669-79. doi: 10.1093/neuonc/nor025.

15.

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA.

Lancet Oncol. 2018 Jun;19(6):768-784. doi: 10.1016/S1470-2045(18)30204-3. Epub 2018 May 16.

16.

Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial.

Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, Michalski A, Campbell RH, Bailey CC, Thorp N, Pizer B, Punt J, Walker DA, Ellison DW, Machin D; Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee.

Eur J Cancer. 2010 Jan;46(1):120-33. doi: 10.1016/j.ejca.2009.09.013.

PMID:
19818598
17.

Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy.

Lafay-Cousin L, Smith A, Chi SN, Wells E, Madden J, Margol A, Ramaswamy V, Finlay J, Taylor MD, Dhall G, Strother D, Kieran MW, Foreman NK, Packer RJ, Bouffet E.

Pediatr Blood Cancer. 2016 Sep;63(9):1527-34. doi: 10.1002/pbc.26042. Epub 2016 May 4. Erratum in: Pediatr Blood Cancer. 2017 Apr;64(4):.

18.

Adult medulloblastoma: clinical profile and treatment results of 18 patients.

Menon G, Krishnakumar K, Nair S.

J Clin Neurosci. 2008 Feb;15(2):122-6. Epub 2007 Dec 19.

PMID:
18078755
19.

Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.

Kaur K, Kakkar A, Kumar A, Purkait S, Mallick S, Suri V, Sharma MC, Julka PK, Gupta D, Suri A, Sarkar C.

J Neurooncol. 2016 Dec;130(3):423-430. Epub 2016 Aug 30.

PMID:
27576698
20.

Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.

Yoon JH, Park KD, Kang HJ, Kim H, Lee JW, Kim SK, Wang KC, Park SH, Kim IH, Shin HY.

World J Pediatr. 2017 Aug;13(4):367-373. doi: 10.1007/s12519-017-0044-3. Epub 2017 May 27.

PMID:
28550392

Supplemental Content

Support Center